No new digest content identified.
National Health Commission of the People’s Republic of China
May 16: Daily briefing on novel coronavirus cases in China
Xi calls for vigilance to combat virus
5 vaccines in China set to finish phase 2 trials in July
China now has five vaccines, one vector and four inactivated, that have entered the first two phases of clinical trials in China, a senior scientist said on May 15. Vaccine recipients in phase II trials have reported no major adverse effects, and these vaccines are set to complete their phase II trials in July.
“As of today, vaccine development is generally progressing smoothly,” Zeng Yixin, deputy director of the National Health Commission, said in a news briefing on Friday.
Zeng said some vaccine candidates are conducting phase I and II clinical trials concurrently in China, which is considered “an innovation” in the emergency approval mechanism of the National Medical Products Administration.
Right now, 2,575 volunteers in total have been administered the five vaccines, including 539 volunteers for phase I trials, Zeng said. “We have gained preliminary data for phase I trials on the vaccines’ safety and ability to create protective antibodies.”
The phase II trials, which enrolled 2,036 volunteers, aim to further evaluate the vaccines’ safety and potency. “Some volunteers are taking more than one dose now, and relevant research is ongoing,” he said.
“We have not recorded any major adverse effects for volunteers in these trials,” he said. “If everything goes according to plan, these projects would finish their phase II trial in July.”…